The first quarter of 2026 has ushered in a regulatory milestone as the European Medicines Agency (EMA) formally integrates 3D-bioprinted tissue validation into its standard drug toxicity protocols. This policy shift is forcing a rapid transition away from traditional animal testing, particularly in the oncology and hepatology sectors across North America and Asia-Pacific. Central to this...
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek